Back to Search Results
Image Place holder

Hayder Saeed, MD

★★★★★
★★★★★
4.8 (189 ratings)
Specialty: Hematology/Oncology
Program: Malignant Hematology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Hodgkin Lymphoma, Non-Hodgkin Lymphoma

Dr. Saeed is an Associate Member in the Moffitt Malignant Hematology program. He earned his MD at the University of Baghdad, College of Medicine, Iraq. He completed a post-doctoral fellowship at the University of Kentucky, College of Pharmacy, in Dr. Abeer Al-Ghananeem’s Lab. Dr. Saeed completed an Internal Medicine Residency and Hematology and Medical Oncology Fellowship, and he served as Chief Fellow at the University of Kentucky. Prior to Moffitt, Dr. Saeed practiced at the University of Kentucky, where he was appointed as an Assistant Professor in the Department of Internal Medicine, Division of Hematology and Blood and Marrow Transplantation, College of Medicine. Dr. Saeed specializes in treating blood cancers. His primary clinical focus includes the management of Non-Hodgkin’s and Hodgkin’s lymphomas. Dr. Saeed’s primary research expertise focuses on early phase clinical trials using novel chemotherapy combinations. He is also interested in understanding blood cancer characteristics and outcomes through population-based studies.


Education & Training

Participating Trials

CLINICAL TRIAL 21096
A Phase I Study of Duvelisib in Combination with CC-486 in Lymphoid Malignancy
Condition: Malignant Hematology
Intervention: CC-486 (Azacitidine (Oral)); Duvelisib ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Shah NN, Castillo-Tokumori F, Whiting J, Boulware D, Sandoval-Sus J, Knepper TC, Hussaini M, Tao J, Chavez JC, Isenalumhe L, Gaballa S, Saeed H, Bello C, Sokol L, Pinilla-Ibarz J, Shah BD. Frontline treatment approaches in TP53-aberrant mantle cell lymphoma. Leuk Lymphoma. 2023 Jan.64(1):230-233. Pubmedid: 36301721.
  • Hess BT, Giri A, Park Y, Patel KK, Link BK, Nowakowski GS, Maliske SM, Fortin S, Chavez JC, Saeed H, Hill BT, Mejia Garcia AV, Maddocks KJ, Hanel W, Wagner-Johnston ND, Messmer MR, Kahl BS, Watkins M, Alderuccio JP, Lossos IS, Nathan S, Orellana-Noia VM, Portell CA, Landsburg DJ, Ayers EC, Castillo JJ. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 Feb.98(2):300-308. Pubmedid: 36588409.
  • Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 Jan.139(3):413-423. Pubmedid: 34570876. Pmcid: PMC8777199.
  • Shah N, Perales MA, Turtle CJ, Cairo MS, Cowan AJ, Saeed H, Budde LE, Tan A, Lee Z, Kai K, Marcondes MQ, Zalevsky J, Tagliaferri MA, Patel KK. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. Future Oncol. 2021 Sep.17(27):3549-3560. Pubmedid: 34154392.
  • Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Ne. 2021 Nov.19(11):1218-1230. Pubmedid: 34781267.
  • Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb.21(2):132-138. Pubmedid: 32950461.
  • Saeed H, Sokol L. Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available Regimens. Clin Lymphoma Myeloma Leuk. 2021 Apr.21(4):199-204. Pubmedid: 33129745.
  • Myint ZW, Shrestha R, Siddiqui S, Slone S, Huang B, Ramlal R, Monohan GP, Hildebrandt GC, Saeed H. Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry. Hematol Oncol Stem Cell Ther. 2020 Mar.13(1):17-22. Pubmedid: 31629724.
  • Myint ZW, Oo TH, Thein KZ, Tun AM, Saeed H. Copper deficiency anemia: review article. Ann Hematol. 2018 Sep.97(9):1527-1534. Pubmedid: 29959467.
  • Saeed H, Yalamanchi S, Liu M, Van Meter E, Gul Z, Monohan G, Howard D, Hildebrandt GC, Herzig R. Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort. Hematol Oncol Stem Cell Ther. 2018 Jun.11(2):90-95. Pubmedid: 29398592.
  • Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017 Jun.28(6):1403. Pubmedid: 28368439.
  • Saeed H, Hnoosh D, Huang B, Durbin EB, McGrath PC, Desimone P, Maynard E, Anthony LB, Dineen SP, Hosein PJ, Tzeng CW. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 Sep.114(4):451-455. Pubmedid: 27238300.
  • Saeed H, Woods RR, Lester J, Herzig R, Gul Z, Monohan G. Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting. Int J Hematol. 2015 Aug.102(2):195-199. Pubmedid: 25997871.
  • Saeed H, Awasthi M, Al-Qaisi A, Massarweh S. Blastic plasmacytoid dendritic cell neoplasm with extensive cutaneous and central nervous system involvement. Rare Tumors. 2014 Oct.6(4):5474. Pubmedid: 25568744. Pmcid: PMC4274438.
  • Chen L, Romond E, Chokshi S, Saeed H, Hodskins J, Stevens M, Pasley G, Weiss H, Massarweh S. A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation. Breast Cancer Res Treat. 2012 Nov.136(2):565-572. Pubmedid: 23053651.
  • Saeed H, Massarweh S. Images in clinical medicine. Hypertrophic pulmonary osteoarthropathy and tripe palms. N Engl J Med. 2012 Jan.366(4):360. Pubmedid: 22276825.
  • Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target. 2010 Jun.18(5):381-388. Pubmedid: 20001275.

Patient Comments
Overall Satisfaction
4.8
★★★★★
★★★★★

189 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments